Article Sidebar

Submitted
Apr 20, 2021
Published
Apr 20, 2021
Download
PDF
Statistic
Read Counter : 70 Download : 43

Main Article Content

Abstract

Proteus syndrome is a very complex and rare to find in the world. It consists of asymmetric and disproportionate overgrowth in bones and skins. There are very few cases that have been come in light all over the world. The responsible genes for the proteus syndrome were AKT1 gene and PTEN.  AKT1 is causing of proliferation, growth in cell cycle and PTEN is tumour suppressor gene in which the change causes the growth in cells. Proteus syndrome is a mutation occurs in chromosomes and it is a disorder not a disease. The major breaks of pathway are commonly found and eventually lead to the clinical approaches as their effect.

Keywords

AKT1 PTEN mTOR PI3K PIP

Article Details

How to Cite
Ved Kumar Mishra, Ayushi Arya, Naveen Dwivedi, Shubha Dwivedi, Ashwani Kumar Singh, Vineeta Singh, & Prashant Kumar Mishra. (2021). A review on AKT1 and PTEN gene of proteus syndrome. International Journal of Research in Pharmacology & Pharmacotherapeutics, 4(2), 158-163. https://doi.org/10.61096/ijrpp.v4.iss2.2015.158-163
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1] Cohen M. M. Jr. and J. A. R. Tibbles The Proteus syndrome: the Elephant Man diagnosed 1986.
  2. [2] Wiedemann HR, Burgio GR, Aldenhoff P, Kunze J, Kaufmann HJ, Schirg E: The proteus syndrome. Partial gigantism of the hands and/or feet, nevi, hemihypertrophy, subcutaneous tumors, macrocephaly or other skull anomalies and possible accelerated growth and visceral affections. Eur J Pediatr 1983; 140: 5–12.
  3. [3] Wiedemann H-R, Burgio GR, Aldenhoff P, Kunze J, Kaufmann HJ, Schirg E. The Proteus syndrome: partial gigantism of the hands and/or feet, nevi, hemihypertrophy, subcutaneous tumors, macrocephaly or other skill anomalies and possible accelerated growth and visceral affections. Eur J Pediatr 1983;140:5–12
  4. [4] Cohen MM Jr, Hayden PW. A newly recognized hamartomatous syndrome. In: O’Donnell JJ, Hall BD, eds. Penetrance and variability in malformation syndromes. The National Foundation— March of Dimes. Birth Defects: Original Article Series 1979;15:291–296
  5. [5] Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet.2006;7:606-19.
  6. [6] Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4:257-62.
  7. [7] Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9-22.
  8. [8] Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000;100:387-90.
  9. [9] CohenMMJr. Causes of premature death in Proteus syndrome. Am J Med Genet 2001; 101:1–3.
  10. [10] Furnari FB, Huang HJ, Cavenee WK. The phosphoinositol phosphatase activity of PTEN mediates a serum- sensitive G1 growth arrest in glioma cells. Cancer Res. 1998;58:5002-8.
  11. [11] Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273:13375-8.
  12. [12] Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science.1997;275:1943-7.
  13. [13] Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356-62.
  14. [14] Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci U S A. 1998;95:15406-11.
  15. [15] Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, Turner J, Cannons JL, Bick D, Blakemore L, Blumhorst C, Brockmann K, Calder P, Cherman N, Deardorff MA, Everman DB, Golas G, Greenstein RM, Kato BM, Keppler-Noreuil KM, Kuznetsov SA, Miyamoto RT, Newman K, Ng D, O'Brien K, Rothenberg S, Schwartzentruber DJ, Singhal V, Tirabosco R, Upton J, Wientroub S, Zackai EH, Hoag K, Whitewood-Neal T, Robey PG, Schwartzberg PL, Darling TN, Tosi LL, Mullikin JC, Biesecker LG (2011). "A mosaic activating mutation in AKT1 associated with the Proteus syndrome". N. Engl. J. Med.365 (7): 611–9. doi:10.1056/NEJMoa1104017. PMC 3170413. PMID 21793738.
  16. [16] Cohen MM (2014). "Proteus syndrome review: molecular, clinical, and pathologic features". Clin. Genet. 85 (2): 111–9. doi:10.1111/cge.12266. PMID 23992099.
  17. [17] Steck P, Pershouse M, Jasser S, Yung W, Lin H, Ligon A et al. (Apr 1997). "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers". Nature Genetics 15 (4): 356–62. doi:10.1038/ng0497-356. PMID 9090379.
  18. [18] Smith JM, Kirk EP, Theodosopoulos G, Marshall GM, Walker J, Rogers M, Field M, Brereton JJ, Marsh DJ (2002). "Germline mutation of the tumour suppressor PTEN in Proteus syndrome". J. Med. Genet. 39 (12): 937–
  19. [19] Cardoso MT, de Carvalho TB, Casulari LA, Ferrari I (2003). "Proteus syndrome and somatic mosaicism of the chromosome 16". Panminerva medica 45 (4): 267–71.PMID 15206168.
  20. [20] Marsh DJ, Trahair TN, Martin JL, Chee WY, Walker J, Kirk EP, Baxter RC, Marshall GM (April 22, 2008). "Rapamycin treatment for a child with germline PTEN mutation". Nature Clinical Practice Oncology 5 (6): 357–361. doi:10.1038/ncponc1112. PMID 18431376.